Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

BACKGROUND: Recognizing resistance or susceptibility to the current standard cisplatin and paclitaxel treatment could improve therapeutic outcomes of metastatic or recurrent cervical cancer. METHODS: Forty-five tissue samples from patients participating in a phase II trial of cisplatin and ifosfamid...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Karageorgopoulou, Sofia, Kostakis, Ioannis D., Gazouli, Maria, Markaki, Sonia, Papadimitriou, Marios, Bournakis, Evangelos, Dimopoulos, Meletios-Athanassios, Papadimitriou, Christos A
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5490227/
https://ncbi.nlm.nih.gov/pubmed/28659181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3435-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires